GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » YoY EBITDA Growth

Veru (STU:FMW) YoY EBITDA Growth : 45.53% (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Veru YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Veru's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 45.53%.

Veru's EBITDA per Share for the three months ended in Jun. 2024 was €-0.07.

Veru YoY EBITDA Growth Historical Data

The historical data trend for Veru's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru YoY EBITDA Growth Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.41 -87.25 149.74 -1,151.58 0.70

Veru Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 85.04 83.30 84.03 45.53

Veru YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Veru's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (A: Sep. 2023 )
=(EBITDA per Share (A: Sep. 2023 )-EBITDA per Share (A: Sep. 2022 ))/ | EBITDA per Share (A: Sep. 2022 ) |
=(-0.992--0.999)/ | -0.999 |
=0.70 %

Veru's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.067--0.123)/ | -0.123 |
=45.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Veru's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » YoY EBITDA Growth
Comparable Companies
ANVS XFOR ALXO ATHA RPTX AGEN PBYI TLSA PDSB ACET OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
VERU:USA FMW:Germany
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Website
https://www.verupharma.com
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru Headlines

No Headlines